60 Degrees Pharmaceuticals Presents at H.C. Wainwright 27th Annual Global Investment Conference on September 9

60 Degrees Pharmaceuticals announced the webcast link and new date for its presentation at the H.C. Wainwright 27th Annual Global Investment Conference. CEO Geoff Dow will present live on September 9 at 3:30 PM ET. The company will also conduct one-on-one meetings during the conference. 60 Degrees Pharmaceuticals is focused on developing new medicines for vector-borne diseases and has received FDA approval for its lead product, ARAKODA, for malaria prevention.

60 Degrees Pharmaceuticals (NASDAQ: SXTP) has announced an updated schedule for its presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation, which was initially scheduled for September 5, has been rescheduled to Tuesday, September 9, 2025, at 3:30 PM ET. The event will be held at the Lotte New York Palace Hotel, with CEO Dr. Geoff Dow delivering a live presentation and the management team available for one-on-one meetings [2].

The company, which specializes in developing and commercializing new medicines for vector-borne diseases, achieved FDA approval for its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. ARAKODA is commercially available in the U.S. and Australia. 60 Degrees Pharmaceuticals collaborates with prominent research and academic organizations to advance its product pipeline [2].

The webcast link for the presentation will be available for interested investors. The company's presentation will provide an opportunity for investors to learn more about its current and future prospects in the vector-borne disease treatment market.

References:
[1] https://www.biospace.com/press-releases/fortress-biotech-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference
[2] https://www.stocktitan.net/news/SXTP/60-degrees-pharmaceuticals-live-webcast-link-and-new-date-for-mora9bnonavv.html